|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Liby KT, Yore MM and Sporn MB:
Triterpenoids and rexinoids as multifunctional agents for the
prevention and treatment of cancer. Nat Rev Cancer. 7:357–369.
2007. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pollier J and Goossens A: Oleanolic acid.
Phytochemistry. 77:10–15. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shanmugam MK, Dai X, Kumar AP, Tan BK,
Sethi G and Bishayee A: Oleanolic acid and its synthetic
derivatives for the prevention and therapy of cancer: Preclinical
and clinical evidence. Cancer Lett. 346:206–216. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bishayee A, Mandal A, Thoppil RJ, Darvesh
AS and Bhatia D: Chemopreventive effect of a novel oleanane
triterpenoid in a chemically induced rodent model of breast cancer.
Int J Cancer. 133:1054–1063. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Deeb D, Gao X, Liu Y, Jiang D, Divine GW,
Arbab AS, Dulchavsky SA and Gautam SC: Synthetic triterpenoid CDDO
prevents the progression and metastasis of prostate cancer in TRAMP
mice by inhibiting survival signaling. Carcinogenesis. 32:757–764.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Konopleva M, Contractor R, Kurinna SM,
Chen W, Andreeff M and Ruvolo PP: The novel triterpenoid CDDO-Me
suppresses MAPK pathways and promotes p38 activation in acute
myeloid leukemia cells. Leukemia. 19:1350–1354. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shao Y, Gao Z, Marks PA and Jiang X:
Apoptotic and autophagic cell death induced by histone deacetylase
inhibitors. Proc Natl Acad Sci USA. 101:18030–18035. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Boucher D, Blais V and Denault JB:
Caspase-7 uses an exosite to promote poly(ADP ribose) polymerase 1
proteolysis. Proc Natl Acad Sci USA. 109:5669–5674. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cory S and Adams JM: Killing cancer cells
by flipping the Bcl-2/Bax switch. Cancer Cell. 8:5–6. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Qiu P, Guan H, Dong P, Li S, Ho CT, Pan
MH, McClements DJ and Xiao H: The p53-, Bax-and p21-dependent
inhibition of colon cancer cell growth by 5-hydroxy
polymethoxyflavones. Mol Nutr Food Res. 55:613–622. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kim W, Yang HJ, Youn H, Yun YJ, Seong KM
and Youn B: Myricetin inhibits Akt survival signaling and induces
Bad-mediated apoptosis in a low dose ultraviolet (UV)-B-irradiated
HaCaT human immortalized keratinocytes. J Radiat Res (Tokyo).
51:285–296. 2010. View Article : Google Scholar
|
|
13
|
Wang X, Bai H, Zhang X, Liu J, Cao P, Liao
N, Zhang W, Wang Z and Hai C: Inhibitory effect of oleanolic acid
on hepatocellular carcinoma via ERK-p53-mediated cell cycle arrest
and mitochondrial-dependent apoptosis. Carcinogenesis.
34:1323–1330. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gilmore TD and Herscovitch M: Inhibitors
of NF-kappaB signaling: 785 and counting. Oncogene. 25:6887–6899.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li TK and Liu LF: Tumor cell death induced
by topoisomerase-targeting drugs. Annu Rev Pharmacol Toxicol.
41:53–77. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Nitiss JL: DNA topoisomerase II and its
growing repertoire of biological functions. Nat Rev Cancer.
9:327–337. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Curtin NJ: Inhibiting the DNA damage
response as a therapeutic manoeuvre in cancer. Br J Pharmacol.
169:1745–1765. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ghavami S, Hashemi M, Ande SR, Yeganeh B,
Xiao W, Eshraghi M, Bus CJ, Kadkhoda K, Wiechec E, Halayko AJ, et
al: Apoptosis and cancer: Mutations within caspase genes. J Med
Genet. 46:497–510. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Call JA, Eckhardt SG and Camidge DR:
Targeted manipulation of apoptosis in cancer treatment. Lancet
Oncol. 9:1002–1011. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ravanan P, Sano R, Talwar P, Ogasawara S,
Matsuzawa S, Cuddy M, Singh SK, Rao GS, Kondaiah P and Reed JC:
Synthetic triterpenoid cyano enone of methyl boswellate activates
intrinsic, extrinsic, and endoplasmic reticulum stress cell death
pathways in tumor cell lines. Mol Cancer Ther. 10:1635–1643. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hyer ML, Shi R, Krajewska M, Meyer C,
Lebedeva IV, Fisher PB and Reed JC: Apoptotic activity and
mechanism of 2-cyano-3, 12-dioxoolean-1,9-dien-28-oic-acid and
related synthetic triterpenoids in prostate cancer. Cancer Res.
68:2927–2933. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Inoue S, Snowden RT, Dyer MJ and Cohen GM:
CDDO induces apoptosis via the intrinsic pathway in lymphoid cells.
Leukemia. 18:948–952. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Altomare DA and Testa JR: Perturbations of
the AKT signaling pathway in human cancer. Oncogene. 24:7455–7464.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ling X, Konopleva M, Zeng Z, Ruvolo V,
Stephens LC, Schober W, McQueen T, Dietrich M, Madden TL and
Andreeff M: The novel triterpenoid C-28 methyl ester of 2-cyano-3,
12-dioxoolen-1, 9-dien-28-oic acid inhibits metastatic murine
breast tumor growth through inactivation of STAT3 signaling. Cancer
Res. 67:4210–4218. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Dai S, Zheng Y, Chen B, Gao M, Zhang Y,
Zhang L, Gong W and He F: Two Gln187 mutants of human soluble APRIL
inhibit proliferation of lung carcinoma A549 cells. Acta Biochim
Pol. 56:703–710. 2009.PubMed/NCBI
|
|
26
|
Datta SR, Dudek H, Tao X, Masters S, Fu H,
Gotoh Y and Greenberg ME: Akt phosphorylation of BAD couples
survival signals to the cell-intrinsic death machinery. Cell.
91:231–241. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ahmad A, Biersack B, Li Y, Kong D, Bao B,
Schobert R, Padhye SB and Sarkar FH: Targeted regulation of
PI3K/Akt/mTOR/NF-κB signaling by indole compounds and their
derivatives: Mechanistic details and biological implications for
cancer therapy. Anticancer Agents Med Chem. 13:1002–1013. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hayden MS and Ghosh S: Shared principles
in NF-kappaB signaling. Cell. 132:344–362. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tully JE, Nolin JD, Guala AS, Hoffman SM,
Roberson EC, Lahue KG, van der Velden J, Anathy V, Blackwell TS and
Janssen-Heininger YM: Cooperation between classical and alternative
NF-κB pathways regulates proinflammatory responses in epithelial
cells. Am J Respir Cell Mol Biol. 47:497–508. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Manna S, Singha B, Phyo SA, Gatla HR,
Chang TP, Sanacora S, Ramaswami S and Vancurova I: Proteasome
inhibition by bortezomib increases IL-8 expression in
androgen-independent prostate cancer cells: the role of IKKalpha. J
Immunol. 191:2837–2846. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Murray RZ and Norbury C: Proteasome
inhibitors as anti-cancer agents. Anticancer Drugs. 11:407–417.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chen G, Han K, Xu X, Du X, Zhang Z, Tang
J, Shi M, Wang M, Li J, Cao B, et al: An anti-leishmanial
thiadiazine agent induces multiple myeloma cell apoptosis by
suppressing the nuclear factor kappaB signalling pathway. Br J
Cancer. 110:63–70. 2014. View Article : Google Scholar :
|
|
33
|
Buss H, Dörrie A, Schmitz ML, Hoffmann E,
Resch K and Kracht M: Constitutive and interleukin-1-inducible
phosphorylation of p65 NF-κB at serine 536 is mediated by multiple
protein kinases including IκB kinase (IKK)-α, IKKβ, IKKε, TRAF
family member-associated (TANK)-binding kinase 1 (TBK1), and an
unknown kinase and couples p65 to TATA-binding protein-associated
factor II31-mediated interleukin-8 transcription. J Biol Chem.
279:55633–55643. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Deng WG, Zhu Y and Wu KK: Up-regulation of
p300 binding and p50 acetylation in tumor necrosis
factor-alpha-induced cyclooxy-genase-2 promoter activation. J Biol
Chem. 278:4770–4777. 2003. View Article : Google Scholar
|
|
35
|
Zhong H, SuYang H, Erdjument-Bromage H,
Tempst P and Ghosh S: The transcriptional activity of NF-kappaB is
regulated by the IkappaB-associated PKAc subunit through a cyclic
AMP-independent mechanism. Cell. 89:413–424. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lagadec P, Griessinger E, Nawrot MP,
Fenouille N, Colosetti P, Imbert V, Mari M, Hofman P, Czerucka D,
Rousseau D, et al: Pharmacological targeting of NF-kappaB
potentiates the effect of the topoisomerase inhibitor CPT-11 on
colon cancer cells. Br J Cancer. 98:335–344. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Nakanishi C and Toi M: Nuclear
factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat
Rev Cancer. 5:297–309. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Xu Y and Villalona-Calero MA: Irinotecan:
Mechanisms of tumor resistance and novel strategies for modulating
its activity. Ann Oncol. 13:1841–1851. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Vos SM, Tretter EM, Schmidt BH and Berger
JM: All tangled up: How cells direct, manage and exploit
topoisomerase function. Nat Rev Mol Cell Biol. 12:827–841. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Pommier Y: Topoisomerase I inhibitors:
Camptothecins and beyond. Nat Rev Cancer. 6:789–802. 2006.
View Article : Google Scholar : PubMed/NCBI
|
